News for Ovid Therapeutics Inc. (OVID)

**media[563181]**

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. ( OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for

Madison Avenue Partners, LP (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Ovid Therapeutics Inc. On De

Oppenheimer has upgraded Ovid Therapeutics (OVID) to outperform from perform, citing its drug candidate OV329. Read more here.

Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocula

Analysis-RFK Jr vow to purge FDA sets up collision with Big Pharma

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of -5.26% and 15.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Marinus reports positive phase 3 seizure treatment trial results

Marinus Pharmaceuticals' patent upheld by PTAB

Ovid stock gets boost from promising OV329 toxicity profile - B.Riley

Ovid reports promising safety profile for epilepsy drug OV329

Oppenheimer sees upside for Marinus Pharmaceuticals stock ahead of key trial results

NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of...

Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

This week, once again, companies across the biotech sector continued to re-evaluate their pipelines and trim their workforces in a bid to conserve cash and extend their financial runway.

Penny stocks are defined by the Securities and Exchange Commission (SEC) as stocks that trade for less than $5 per share. They exhibit high price volatility due to their low pricing.

Loading... Loading... Shares of Ovid Therapeutics Inc OVID dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoin...

Loading... Loading... Shares of Nurix Therapeutics, Inc. NRIX rose sharply in today's pre-market trading after the company announced results from its ongoing c...

In this article, we will take a detailed look at the 20 countries with the highest rates of epilepsy with insights into number of epilepsy cases by country and population.